Nuvalent, Inc. (NUVL)
$102.42
Performance
- $101.76$103.54$102.42
0.64%
Downside
Day's Volatility :1.71%
Upside
1.08%
- $49.02$113.51$102.42
52.14%
Downside
52 Weeks Volatility :56.81%
Upside
9.77%
Returns
| Period | Nuvalent, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 26.81% | 4.7% | 0.0% |
6 Months | 58.23% | 11.6% | 0.0% |
1 Year | 78.21% | 18.9% | 0.0% |
3 Years | 418.26% | 20.9% | -21.9% |
Highlights
Market Capitalization | 7.3B |
Book Value | $9.84 |
Earnings Per Share (EPS) | -2.79 |
Wall Street Target Price | 113.55 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -22.71% |
Return On Equity TTM | -32.81% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -2.79 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.51 |
EPS Estimate Next Year | -4.28 |
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Next Quarter | -0.79 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 10.87%
Technicals Summary
Sell
Neutral
Buy
Nuvalent, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nuvalent, Inc. | -7.92% | 58.23% | 78.21% | 418.26% | 450.88% |
 Regeneron Pharmaceuticals, Inc. | -12.04% | 12.88% | 20.22% | 83.33% | 233.83% |
 Novo Nordisk A/s | -12.51% | -3.33% | 18.42% | 134.08% | 356.57% |
 Alnylam Pharmaceuticals, Inc. | 4.79% | 91.82% | 69.4% | 35.85% | 250.43% |
 Vertex Pharmaceuticals Incorporated | -0.94% | 22.01% | 29.63% | 166.72% | 175.25% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nuvalent, Inc. | NA | NA | NA | -3.51 | -0.33 | -0.23 | NA | 9.84 |
Regeneron Pharmaceuticals, Inc. | 26.87 | 26.87 | 1.38 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.83 | 40.83 | 1.84 | 3.37 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.43 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nuvalent, Inc. | Buy | $7.3B | 450.88% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.9B | 233.83% | 26.87 | 32.04% |
Novo Nordisk A/s | Buy | $535.2B | 356.57% | 40.83 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 250.43% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $125.1B | 175.25% | 32.84 | -4.74% |
Institutional Holdings
Deerfield Management Co
28.34%FMR Inc
12.57%Paradigm Biocapital Advisors LP
6.48%Vanguard Group Inc
5.35%BlackRock Inc
4.29%Bain Capital Life Sciences Investors, LLC
3.82%
Company Information
nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.
Organization | Nuvalent, Inc. |
Employees | 115 |
CEO | Dr. James R. Porter Ph.D. |
Industry | Services |
